The authors comprehensively review the anticancer genes and gene delivery methods currently available for cancer gene therapy, including the transfer of genetic material into the cancer cells, stimulation of the immune system to recognize and eliminate cancer cells, and the targeting of the nonmalignant stromal cells that support their growth.

Cancer Gene Therapy.- The Genetic Basis of Cancer.- Tumor Suppressor Gene Replacement for Cancer.- Antisense Technology.- Cancer Therapeutic Applications of Ribozymes and RNAi.- Fusogeneic Membrane Glycoproteins for Cancer Gene Therapy.- Suicide Gene Therapy.- Molecular Chemotherapy Approaches.- Genetic Immunotherapy Approaches.- Immunotherapy of Cancer by Dendritic Cell-Targeted Gene Transfer.- Dendritic Cells.- Polynucleotide Immunization for Cancer Therapy.- Development of Oncolytic Replication-Competent Herpes Simplex Virus Vectors.- Development of Oncolytic Adenoviruses.- Conditionally Replicating Adenoviruses for Cancer Treatment.- Reovirus as an Oncolytic Agent.- Antiangiogenic Gene Therapy of Cancer.- Proapoptotic Strategy in Cancer Gene Therapy.- Antimetastasis.- Antimetastatic Gene Therapy.- Drug Resistance Gene Transfer as an Antitumor Strategy.- Chemosensitization.- Radiosensitization by Gene Therapy.- Nonviral Vector Systems for Cancer Gene Therapy.- Viral Vectors for Cancer Gene Therapy.- Bacterial Systems for Tumor-Specific Gene Therapy.- Molecular Imaging of Cancer Gene Therapy.- Cancer-Related Gene Therapy Clinical Trials.- Regulatory Aspects in the Development of Gene Therapies.

Today a new generation of powerful cancer therapeutics targeted against the molecular pathways that produce malignant phenotypes is rapidly emerging. In Cancer Gene Therapy, leading basic and clinical cancer oncologists provide a complete introduction and guide to the latest developments in cancer gene therapy-from bench to bedside. In their discussions, the authors comprehensively review the anticancer genes and gene delivery methods currently available for cancer gene therapy, including the transfer of genetic material into the cancer cells, stimulation of the immune system to recognize and eliminate cancer cells, and the targeting of the nonmalignant stromal cells that support their growth. They also thoroughly examine the advantages and limitations of the different therapies and detail strategies to overcome obstacles to their clinical implementation. Topics of special interest include vector-targeting techniques, the lessons learned to date from clinical trials of cancer gene therapy, and the regulatory guidelines for future trials. Noninvasive techniques to monitor the extent of gene transfer and disease regression during the course of treatment are also discussed.
Authoritative and wide ranging, Cancer Gene Therapy offers a comprehensive survey of the molecular basis of cancer gene therapy and demonstrates its enormous potential to take a place in the clinic alongside the current generation of anticancer therapeutics.

GPSR Compliance The European Union's (EU) General Product Safety Regulation (GPSR) is a set of rules that requires consumer products to be safe and our obligations to ensure this. If you have any concerns about our products you can contact us on ProductSafety@springernature.com. In case Publisher is established outside the EU, the EU authorized representative is: Springer Nature Customer Service Center GmbH Europaplatz 3 69115 Heidelberg, Germany ProductSafety@springernature.com